ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

VIVAZEN® and MoreBetter® Announce Landmark Real-World Evidence Study on Its Proprietary Extract, Highlighting the Power of Botanicals in Daily Wellness

VIVAZEN®, a trusted leader in botanical-based wellness products, proudly shares the results of a first-of-its-kind Real-World Evidence (RWE) study using its proprietary extract. The study was conducted in partnership with MoreBetter®, a leading real-world data and research platform. The study tracked the daily experiences of real users over 21 days and revealed statistically significant improvements in energy, focus, and productivity without the use of caffeine or stimulants.*

Scientifically Measured, Naturally Effective

The RWE study provided consistent daily feedback on the Energy + Focus supplement, a proprietary formula, which resulted in measurable and meaningful outcomes:

  • 25% increase in daily energy*
  • 66% reported improved productivity*
  • 63% experienced reduced fatigue*
  • 61% noted better focus*

“This study exemplifies how real-world evidence can transform anecdotal usage into actionable science,” said Steve Curtis, CEO of VIVAZEN. “Botanicals have played a critical role in traditional health practices for centuries, but research like this is essential to bring credibility and scientific rigor to the future of functional wellness.”

Why This Research Matters Now

In July 2025, the FDA announced plans to schedule 7-hydroxymitragynine (7-OH), a potent synthetic derivative of kratom, as a Schedule I controlled substance, citing its opioid-like risks and safety data. Crucially, regulators emphasized that natural kratom leaf products are not the target of this action.

Amid growing concern over adulterated products, this study offers timely, real-world data to distinguish authentic botanical formulas from dangerous synthetics and reinforces the need for science-based evaluation of kratom in everyday use.

Advancing Wellness Through Research & Transparency

To help advance public understanding and transparency, VIVAZEN partnered with the Network of Applied Pharmacognosy (NAP), a nonprofit dedicated to accelerating research and education around natural medicines by centering lived experience and community engagement. In alignment with this mission, NAP has published a summary of the study findings on its public platform, making the results more accessible to researchers, educators, and everyday consumers alike. Read the full blog post here

Help Shape the Future of Botanical Science

This RWE study highlights a broader movement to validate natural products through real-world data, offering consumers and health care providers a clearer understanding of product efficacy outside of a lab environment. As consumers increasingly seek non-synthetic, plant-based alternatives, real-world studies provide critical insights that help build trust, transparency, and scientific credibility.

If you’re interested in helping advance the science of botanicals, sign up to participate in future studies here

Note: The study mentioned is based on self-reported data and individual experiences; results may vary.

*VIVAZEN® products are not intended to diagnose, treat, cure or prevent any disease and these statements have not been evaluated by the FDA.

Amid growing concern over adulterated products, this study offers timely, real-world data to distinguish authentic botanical formulas from dangerous synthetics and reinforces the need for science-based evaluation of kratom in everyday use.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+1.37 (0.56%)
AAPL  268.47
-1.30 (-0.48%)
AMD  233.54
-4.16 (-1.75%)
BAC  53.20
-0.09 (-0.17%)
GOOG  279.70
-5.64 (-1.98%)
META  621.71
+2.77 (0.45%)
MSFT  496.82
-0.28 (-0.06%)
NVDA  188.15
+0.07 (0.04%)
ORCL  239.26
-4.54 (-1.86%)
TSLA  429.52
-16.39 (-3.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.